Chapter 15
Pharmacotherapy of Depression and Anxiety Disorders
Chapter 15
Pharmacotherapy of Depression and Anxiety Disorders
Depression is a common mental illness that manifests as major depression, persistent depressive disorder, and bipolar I and II disorders.
It can be …
Antidepressant drugs alleviate symptoms of depression by enhancing neurotransmission in the brain.
These agents are classified based on their chemical …
Tricyclic antidepressants, or TCAs, are first-generation antidepressants.
They block serotonin and norepinephrine reuptake transporters while inhibiting …
Monoamine oxidase inhibitors, or MAOIs, inhibit monoamine oxidase, increasing neurotransmitter levels.
Atypical antidepressants encompass drugs with …
Neurodegenerative disorders are progressive conditions characterized by the irreversible loss of neurons in specific brain regions.
The primary …
Parkinson's Disease or PD is a neurodegenerative disorder characterized by an imbalance between cholinergic and reduced dopaminergic neurons.
The …
Alzheimer's disease, or AD, is a neurodegenerative disorder primarily affecting older adults, causing impaired memory and cognitive decline through …
The goal of Alzheimer's disease or AD pharmacotherapy is to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms, …
The present protocol describes the Conditioned Place Preference (CPP) as a model of relapse in drug addiction. In this model, animals are first trained to …
In addition to the standardized use of antidepressant medications and psychotherapy, the usage of traditional Chinese medicine has lead to an overall …
Sleep, an essential component of health and overall well-being, often presents challenges for older individuals who frequently experience sleep disorders …